$DARE
Dare Bioscience, Inc. Stock $dare

$dare Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000140191423000048 Filed on November 09, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$1.808M	$1.000M	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.180M	$2.720M	$3.254M
YoY Change	-2.28%	1.62%	34.09%
% of Gross Profit
Research & Development	$3.800M	$6.675M	$12.98M
YoY Change	-70.72%	49.58%	82.35%
% of Gross Profit
Depreciation & Amortization	$8.360K	$10.00K	$10.62K
YoY Change	-21.28%	230.03%	50.85%
% of Gross Profit
Operating Expenses	$6.979M	$9.396M	$16.23M
YoY Change	-57.0%	31.62%	70.08%
Operating Profit		-$8.396M
YoY Change		17.62%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$113.9K	$97.32K	$287.3K
YoY Change	-60.36%	-18.18%	34519.28%
Pretax Income	-$5.058M	-$8.300M	-$15.94M
YoY Change	-68.28%	18.24%	67.08%
Income Tax
% Of Pretax Income
Net Earnings	-$5.058M	-$8.299M	-$15.94M
YoY Change	-68.28%	18.22%	67.08%
Net Earnings / Revenue	-279.75%	-829.91%
Basic Earnings Per Share		-$0.09
Diluted Earnings Per Share	-$0.06	-$0.09	-$0.20
COMMON SHARES
Basic Shares Outstanding	98.56M shares	87.79M shares	84.83M shares
Diluted Shares Outstanding		91.05M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.48M	$13.89M	$34.67M
YoY Change	-69.78%	-65.61%	-32.91%
Cash & Equivalents	$10.48M	$13.90M	$34.67M
Short-Term Investments
Other Short-Term Assets	$6.118M	$831.4K	$6.666M
YoY Change	-8.22%	-87.93%	169.16%
Inventory
Prepaid Expenses	$6.118M	$6.580M	$6.666M
Receivables
Other Receivables	$949.2K	$1.130M	$1.703M
Total Short-Term Assets	$17.54M	$22.44M	$43.04M
YoY Change	-59.24%	-54.74%	-22.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.976M	$58.62K	$64.91K
YoY Change	2943.71%	-19.51%	149.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.763M	$796.4K	$722.7K
YoY Change	143.95%	8.14%	48.98%
Total Long-Term Assets	$3.739M	$2.619M	$787.6K
YoY Change	374.67%	223.54%	54.09%
TOTAL ASSETS
Total Short-Term Assets	$17.54M	$22.44M	$43.04M
Total Long-Term Assets	$3.739M	$2.619M	$787.6K
Total Assets	$21.28M	$25.05M	$43.83M
YoY Change	-51.44%	-50.27%	-21.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.386M	$4.987M	$2.028M
YoY Change	66.94%	43.43%	-3.57%
Accrued Expenses	$3.358M	$5.293M	$10.89M
YoY Change	-69.18%	27.97%	247.36%
Deferred Revenue		$205.2K	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.48M	$26.34M	$31.62M
YoY Change	-35.24%	15.35%	97.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.849M	$1.000M	$1.090M
YoY Change	436.47%	-16.29%
Total Long-Term Liabilities	$5.849M	$1.000M	$1.090M
YoY Change	436.47%	-16.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.48M	$26.34M	$31.62M
Total Long-Term Liabilities	$5.849M	$1.000M	$1.090M
Total Liabilities	$26.33M	$27.34M	$32.71M
YoY Change	-19.52%	13.77%	91.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$171.2M	-$166.2M	-$141.1M
YoY Change	21.33%	32.85%	28.12%
Common Stock	$166.5M	$164.3M	$152.5M
YoY Change	9.19%	8.09%	2.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.048M	-$2.289M	$11.11M
YoY Change
Total Liabilities & Shareholders Equity	$21.28M	$25.05M	$43.83M
YoY Change	-51.44%	-50.27%	-21.47%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	-$5.058M	-$8.299M	-$15.94M
YoY Change	-68.28%	18.22%	67.08%
Depreciation, Depletion And Amortization	$8.360K	$10.00K	$10.62K
YoY Change	-21.28%	230.03%	50.85%
Cash From Operating Activities	-$8.177M	-$7.980M	-$5.897M
YoY Change	38.67%	-192.79%	-40.53%
INVESTING ACTIVITIES
Capital Expenditures	$609.4K	$20.00K	$2.700K
YoY Change	22471.48%	-136.36%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$609.4K	-$20.00K	-$2.700K
YoY Change	22471.48%	-63.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.307M	8.580M	-10.00
YoY Change	-53071300.0%	192276.68%	-100.0%
NET CHANGE
Cash From Operating Activities	-8.177M	-7.980M	-5.897M
Cash From Investing Activities	-609.4K	-20.00K	-2.700K
Cash From Financing Activities	5.307M	8.580M	-10.00
Net Change In Cash	-3.479M	580.0K	-5.899M
YoY Change	-41.03%	-93.22%	-196.9%
FREE CASH FLOW
Cash From Operating Activities	-$8.177M	-$7.980M	-$5.897M
Capital Expenditures	$609.4K	$20.00K	$2.700K
Free Cash Flow	-$8.786M	-$8.000M	-$5.899M
YoY Change	48.93%	-192.43%	-40.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	0	shares
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	205206	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	194586	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	398391	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	26342770	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31623927	usd
CY2023Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1000000	usd
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	dare	License Fee Expense LicenseFeeExpense	25000	usd
CY2022Q3	dare	License Fee Expense LicenseFeeExpense	25000	usd
	dare	License Fee Expense LicenseFeeExpense	75000	usd
	dare	License Fee Expense LicenseFeeExpense	75000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	9396415	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	7138793	usd
	us-gaap	Operating Expenses OperatingExpenses	26768420	usd
	us-gaap	Operating Expenses OperatingExpenses	25154921	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8396415	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7138793	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25768420	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15154921	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	97319	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	118950	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25103829	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15004515	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8299096	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7019843	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25103829	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15004515	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-15030	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-230748	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-68186	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-375767	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8314126	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7250591	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25172015	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15380282	usd
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91051642	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91051642	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	84822516	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	84822516	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	87221575	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85553134	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11112110	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	624621	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1299375	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8042501	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22005	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4971600	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	650186	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	452195	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8762232	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-31151	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2719402	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	636086	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	8108702	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-8299096	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-15030	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2288740	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	38754321	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	532409	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-8398670	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-9150	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	30878910	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	537521	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1218750	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	120149	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	413998	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-135869	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	33033459	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	556448	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4456	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7019843	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-230748	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	26343772	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15004515	usd
	us-gaap	Depreciation Depreciation	28383	usd
	us-gaap	Depreciation Depreciation	13580	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1910893	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1626378	usd
	dare	Non Cash Lease Expense NonCashLeaseExpense	-18602	usd
	dare	Non Cash Lease Expense NonCashLeaseExpense	29320	usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	46477	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-573401	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1146724	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-86053	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4408886	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	1752975	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	0	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	831379	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-77939	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	24764	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2959446	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1374109	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6068350	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1000086	usd
	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	2641232	usd
	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	-4293433	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	205206	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30677749	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12191757	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22099	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	60372	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22099	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-60372	usd
	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	8560897	usd
	dare	Net Proceeds From Issuance Of Common Stock And Warrants NetProceedsFromIssuanceOfCommonStockAndWarrants	1218750	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	124605	usd
	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	1299375	usd
	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	601174	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	133594	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10327852	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1343355	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-68185	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-375767	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20440181	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11284541	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34669605	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51674087	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14229424	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40389546	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13894424	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40389546	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	335000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	0	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14229424	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40389546	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	585942	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	300000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-166200000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13900000	usd
CY2023Q3	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	15700000	usd
CY2023Q3	dare	Working Capital Increase Deficit WorkingCapitalIncreaseDeficit	-3900000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25100000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-30700000	usd
	dare	Periodof Insufficient Cashand Liquidity Requirements PeriodofInsufficientCashandLiquidityRequirements	P12M
	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	1353515	shares
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1300000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	200000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	195000	usd
CY2023Q3	dare	Insurance Financing Premiums Taxes And Fees Amount InsuranceFinancingPremiumsTaxesAndFeesAmount	800000	usd
CY2023Q3	dare	Insurance Financing Interest Rate InsuranceFinancingInterestRate	0.080
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	500000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10006500	shares
CY2018Q3	us-gaap	Net Rentable Area NetRentableArea	3169	sqft
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-504000	usd
CY2022	dare	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-458000	usd
CY2022	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	46000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	182000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	195000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	469000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	231000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y6M29D
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19470388	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7993569	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19470388	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7993569	shares

Files In Submission

Name	View Source	Status
dare-20230930_cal.xml	Edgar Link	unprocessable
dare-20230930_htm.xml	Edgar Link	completed
0001401914-23-000048-index-headers.html	Edgar Link	pending
0001401914-23-000048-index.html	Edgar Link	pending
0001401914-23-000048.txt	Edgar Link	pending
0001401914-23-000048-xbrl.zip	Edgar Link	pending
dare-20230930.htm	Edgar Link	pending
dare-20230930.xsd	Edgar Link	pending
dare-20230930_g1.jpg	Edgar Link	pending
exhibit102_10q20230930.htm	Edgar Link	pending
exhibit311_20230930.htm	Edgar Link	pending
exhibit312_20230930.htm	Edgar Link	pending
exhibit321_20230930.htm	Edgar Link	pending
exhibit322_20230930.htm	Edgar Link	pending
ex_103performancebonusplan.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
dare-20230930_def.xml	Edgar Link	unprocessable
dare-20230930_lab.xml	Edgar Link	unprocessable
dare-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DARE
Dare Bioscience, Inc. Stock $dare

2023 Q4 Form 10-Q Financial Statement

#000140191423000048 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE Dare Bioscience, Inc. Stock $dare

2023 Q4 Form 10-Q Financial Statement

#000140191423000048 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE
Dare Bioscience, Inc. Stock $dare